Hercules, California, and Lugano, Switzerland — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, and Inpeco, a leading company in the field of laboratory automation, today announced that they have entered into a development agreement to build interfaces between Bio-Rad’s clinical diagnostics platforms for diabetes, autoimmune disease, and infectious disease testing and Inpeco’s FlexLab™ 3.6 system. Connecting Bio-Rad instruments to the Inpeco FlexLab 3.6 will offer clinical diagnostics laboratories a complete and integrated solution that automates sample processing, consolidates testing platforms, and improves operating efficiency of the instruments.

With increasing test volumes and the demand for faster turnaround times, many laboratories are implementing total laboratory automation solutions. Automated track systems prepare, sort, and transport patient samples between instruments, eliminating the need for manual intervention.

The first Bio-Rad systems to be interfaced to the FlexLab 3.6 are the VARIANT™ II TURBO hemoglobin testing system and the BioPlex® 2200 system. The VARIANT II TURBO system is a fully-automated system that uses high-performance liquid chromatography (HPLC) to deliver fast and precise measurement of hemoglobin A1C, which is used to monitor average blood glucose levels over time in patients with diabetes. The BioPlex 2200 system uses proprietary multiplex chemistry to deliver full automation and random access testing for autoimmune diseases and infectious diseases.

“We are pleased to work with Inpeco to connect two of Bio-Rad’s highly successful diagnostics testing systems to the Inpeco FlexLab 3.6 automated track system,” said John Goetz, Bio-Rad executive vice president and Clinical Diagnostics Group president. “By working with Inpeco, we can provide our customers the benefits of our VARIANT II TURBO and BioPlex 2200 systems along with the workflow efficiencies of total laboratory automation.”

“We are extremely pleased about this agreement, which represents a significant step forward in the expansion of the list of analyzers that can be connected to our automation systems,” said Andrea Pedrazzini, president of Inpeco Group. “Bio-Rad instruments will expand Inpeco’s automation, allowing customers to choose the workstation configuration they prefer for complete laboratory automation.”

About Inpeco

Since 1990, Inpeco has specialized in providing automation solutions to improve and simplify the process and operations of laboratories. With expertise in automation, robotics, sample and data management, and patient-related activities, Inpeco develops and manufactures products to help laboratories improve operational efficiency. Product quality and innovation are major goals. For more information, visit https://www.inpeco.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for 60 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.